Jan 04, 2022 11:32 PM (GMT+8) · EqualOcean
On January 4, 2022, Junshi biology announced the termination of its promotion cooperation with AstraZeneca. In February 28, 2021, the collaboration between Jun Shi and Ashley kangdacheng, exclusive application rights granted by the company of PD-1 to the trial of the urinary tract tumor in Chinese mainland, and the exclusive promotion right of all approved indications in non core city areas. With the gradual maturity of the commercialization team built by Junshi biology, more indications of treprizumab injection have been successfully included in the latest version of the national medical insurance catalogue. In order to better implement the company's product commercialization promotion strategy in the next development stage and actively respond to the future market competition pattern, through friendly negotiation between the two sides, on December 31, 2021, Junshi biological signed the termination agreement of exclusive promotion agreement with AstraZeneca pharmaceutical, and Junshi biological officially withdrew the promotion right of treprizumab injection.
Related companies: